Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07103408
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
A Phase II Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) for Limited-stage Small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Conditions
Small-Cell Lung Cancer (SCLC)
Interventions
Consolidative therapy Immuno-chemotherapy Radiotherapy
Updated 1 time since 2025 Last updated: Aug 2, 2025 Started: Oct 1, 2025 Primary completion: Sep 30, 2029 Completion: Sep 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07103408, this PHASE2 trial focuses on Small-Cell Lung Cancer (SCLC) and remains actively recruiting participants. Sponsored by Sun Yat-sen University, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sun Yat-sen University
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .